ライフサイエンスコーパス: HIV disease progression

1 r this virus is a marker or a determinant of HIV disease progression.

2 in CD8 lymphocyte function that accompanies HIV disease progression.

3 tially participate in the pathophysiology of HIV disease progression.

4 tegrity, and are associated with accelerated HIV disease progression.

5 ects and lower d(N)/d(S) in those with rapid HIV disease progression.

6 or (nef) has been positively correlated with HIV disease progression.

7 8 months is strongly associated with risk of HIV disease progression.

8 , many of which are implicated in more rapid HIV disease progression.

9 the identification of viral determinants of HIV disease progression.

10 n suggested a link between GSH depletion and HIV disease progression.

11 ine environment, which may be altered during HIV disease progression.

12 s experienced, the greater the risk of early HIV disease progression.

13 s associated with an increased rate of early HIV disease progression.

14 no adverse effects on hemoglobin decrease or HIV disease progression.

15 ociated with increased T-cell activation and HIV disease progression.

16 s system damage, but also risk of more rapid HIV disease progression.

17 (HIV) burdens have each been correlated with HIV disease progression.

18 eductions in cytotoxic lymphocytes influence HIV disease progression.

19 herapies utilizing this cytokine for slowing HIV disease progression.

20 with higher levels of immune activation and HIV disease progression.

21 nd immune activation, which is implicated in HIV disease progression.

22 ) and substance abuse is known to accelerate HIV disease progression.

23 sis, sTim-3 may represent a new correlate of HIV disease progression.

24 Thus, plasma sTim-3 shedding correlated with HIV disease progression.

25 during pathogenic SIV infection may prevent HIV disease progression.

26 ylori infection with favorable parameters of HIV disease progression.

27 ociated with increased immune activation and HIV disease progression.

28 bout the effect of hepatitis co-infection on HIV disease progression.

29 se alleles appear equally protective against HIV disease progression.

30 1 patients, has been suggested to accelerate HIV disease progression.

31 are the HLA alleles most protective against HIV disease progression.

32 generalized immune activation and accelerate HIV disease progression.

33 ciated CD4(+) T-cell decline, a predictor of HIV disease progression.

34 immunization strategies aimed at preventing HIV disease progression.

35 GF-basic) cytokines that have been linked to HIV disease progression.

36 or the striking age-dependent differences in HIV disease progression.

37 ial examining the effect of multivitamins on HIV disease progression.

38 tract dysfunction may influence the rate of HIV disease progression.

39 healthcare, GO does not play a major role in HIV disease progression.

40 immunodeficiency virus (HIV) load and slower HIV disease progression.

41 ne activation might be of benefit in slowing HIV disease progression.

42 ter breastfeeding cessation affects maternal HIV disease progression.

43 ric deworming of adults with HIV in delaying HIV disease progression.

44 sensitivity responses in healthy persons and HIV disease progression.

45 immunization strategies aimed at preventing HIV disease progression.

46 flicting reports regarding effects of HCV on HIV disease progression.

47 IV) infection and are highly correlated with HIV disease progression.

48 AART) when estimating the effect of HAART on HIV disease progression.

49 , they suggest HIV-Tat as a key regulator of HIV disease progression.

50 ed with better pregnancy outcomes and slowed HIV disease progression.

51 that stress and depression have an impact on HIV disease progression.

52 urs in HIV(+) patients and may contribute to HIV disease progression.

53 alleles that have been associated with slow HIV disease progression.

54 nd accelerated human immunodeficiency virus (HIV) disease progression.

55 of accelerated human immunodeficiency virus (HIV) disease progression.

56 mic failure in human immunodeficiency virus (HIV) disease progression.

57 mechanisms of human immunodeficiency virus (HIV) disease progression.

58 ce the rate of human immunodeficiency virus (HIV) disease progression.

59 f pregnancy on human immunodeficiency virus (HIV) disease progression.

60 infection, and suggested as an indicator of HIV disease progression (AIDS and death).

61 al response serves as an immune correlate of HIV disease progression and a potential qualifying facto

62 antigen specific CD4 T cell activation with HIV disease progression and AIDS-related central nervous

63 cy virus (HIV), but its long-term effects on HIV disease progression and comorbidities are unknown.

64 could be a target for interventions to slow HIV disease progression and extend the time before use o

65 n the impact of nutritional interventions on HIV disease progression and HAART response.

66 L2 genotypes are independent determinants of HIV disease progression and heterozygosity for MBL2 codi

67 by flow cytometry and their correlation with HIV disease progression and immune activation.

68 ts, are associated with an increased risk of HIV disease progression and mortality.

69 Active drug use is temporally linked to HIV disease progression and mortality.

70 thy, all of which are key factors that drive HIV disease progression and non-HIV comorbidities; howev

71 Micronutrient supplements can delay HIV disease progression and reduce mortality in HIV-posi

72 ne treatment experience demonstrated reduced HIV disease progression and reduced mortality with PI tr

73 iretroviral therapy (ART) adherence predicts HIV disease progression and survival, but its effect on

74 y aims to identify the mucosal correlates of HIV disease progression and to determine the molecular c

75 y an important role during various stages of HIV disease progression and transmission.

76 Prevention of HIV disease progression and vertical transmission, impro

77 nts and reduce human immunodeficiency virus (HIV) disease progression and mortality among individuals

78 ed as an appropriate surrogate end point for HIV disease progression, and it is currently used as the

79 fects of iron supplementation on hemoglobin, HIV disease progression, and morbidity.

80 ve at reducing infectious disease morbidity, HIV disease progression, and poor pregnancy outcomes in

81 ship between the number of circulating IPCs, HIV disease progression, and the occurrence of HIV-relat

82 inflammation, human immunodeficiency virus (HIV) disease progression, and death.

83 oire diversity changes in whole blood during HIV disease progression are primarily the result of chan

84 t predictor of human immunodeficiency virus (HIV) disease progression are needed for individuals init

85 nvolved in the increased HIV replication and HIV disease progression associated with multiple opportu

86 oral triple therapy is effective at halting HIV disease progression, but can have toxic effects and

87 unodeficiency virus (HIV) RNA level predicts HIV disease progression, but the extent to which it expl

88 re focus on HLA-B*14, which protects against HIV disease progression, but the immunodominant HLA-B*14

89 function, measured by sj/beta-TREC ratio, in HIV disease progression by analyzing a large number of p

90 Variability in human immunodeficiency virus (HIV) disease progression cannot be fully predicted by CD

91 During HIV disease progression, CD28 expression is lost, partic

92 or more in the treatment group had a reduced HIV disease progression compared with those in the place

93 oms among women with HIV are associated with HIV disease progression, controlling for clinical, subst

94 ns who have stable CD4+ T-cell counts and no HIV disease progression despite years of HIV infection -

95 n follow-up, 15 months), and there were 2374 HIV disease progression events and 453 observed deaths (

96 No significant difference in HIV disease progression existed between participants in

97 An additional analysis of the time to HIV disease progression implicated two genes, one of whi

98 we examined potential correlates of delayed HIV disease progression in 51 HIV-1-infected African chi

99 fect of empiric deworming in the delaying of HIV disease progression in adults with HIV in an area wh

100 Alternative approaches are needed to delay HIV disease progression in areas where co-infections are

101 cted tissues and could potentially influence HIV disease progression in coinfected individuals throug

102 e potential contribution of viral factors to HIV disease progression in eight infants selected from a

103 s individuals and partial protection against HIV disease progression in heterozygotes.

104 iency virus (HIV) expression and accelerated HIV disease progression in HIV-infected persons.

105 A3G's contribution to the protection against HIV disease progression in humans, we quantified hA3G mR

106 early cytomegalovirus infection accelerates HIV disease progression in infants.

107 pecific CTL contribute to protection against HIV disease progression in infected individuals with B*3

108 regnancy was associated with a lower risk of HIV disease progression in this HAART-era study.

109 ith higher T-cell immune activation and with HIV disease progression in treated and untreated individ

110 enotype has been associated with the rate of HIV disease progression in untreated patients, little is

111 ment of viral genetic factors in determining HIV disease progression in vivo.

112 sibly IGF-I) are associated with the rate of HIV disease progression in women and, more broadly, that

113 lationship between depression, immunity, and HIV disease progression in women.

114 cceleration of human immunodeficiency virus (HIV) disease progression in women who have a pregnancy w

115 HIV disease progression is characterized by numerous pat

116 e of the major structural gene gagIMPORTANCE HIV disease progression is known to differ between indiv

117 , the HLA-B*14-associated protection against HIV disease progression is significantly greater for HLA

118 , if infection ensues, that slow the rate of HIV disease progression is still incomplete and will req

119 Human immunodeficiency virus (HIV) disease progression is associated with a helper T c

120 determinant of human immunodeficiency virus (HIV) disease progression, is the result of a complex int

121 the morbidity and mortality associated with HIV disease progression, it has also provided new avenue

122 surements have been central to understanding HIV disease progression, making important clinical decis

123 aboratory markers currently used to evaluate HIV disease progression may be associated with subsequen

124 rks offer further support to the notion that HIV disease progression may be dependent on complex inte

125 d effector memory subsets and correlate with HIV disease progression, measured by viral load, CD4 per

126 life stress increased the odds of developing HIV disease progression nearly fourfold.

127 Attenuating effects of acyclovir on HIV disease progression observed in recent clinical tria

128 the HLA-B locus has the strongest impact on HIV disease progression of any polymorphisms within the

129 We investigated rates of HIV disease progression of clade C-infected South Africa

130 Similar effects were noted for late-stage HIV disease progression on information processing speed

131 ) have recently been shown to correlate with HIV disease progression or control.

132 supplements did not result in a decrease in HIV disease progression or death but may have resulted i

133 MAIN OUTCOME MEASURE: The composite of HIV disease progression or death from any cause.

134 e supplementation did not reduce the risk of HIV disease progression or death.

135 n during and after pregnancy did not improve HIV disease progression or pregnancy outcomes, but may i

136 onths) showed a significantly higher risk of HIV-disease progression or death in patients receiving z

137 ance to HIV infection (odds ratio, 0.97), or HIV disease progression (P > .05).

138 s that may contribute to the pathogenesis of HIV disease progression, pathways that might not be a di

139 mber of patients in 3 cohorts with different HIV disease progression phenotypes.

140 iation of these discrete HLA supertypes with HIV disease progression rates in a population of HIV-inf

141 k for eventual human immunodeficiency virus (HIV) disease progression remains high.

142 macrophages in human immunodeficiency virus (HIV) disease progression remains incompletely defined.

143 ated with slow human immunodeficiency virus (HIV) disease progression, supporting the important role

144 ee virus in BALF was a stronger predictor of HIV disease progression than was lymphocytic alveolitis.

145 Given their utility as surrogate markers of HIV disease progression, this suggests limited evidence

146 infection and human immunodeficiency virus (HIV) disease progression, two studies were done among a

147 The effect of coinfection on HIV disease progression varied with species.

148 deficiency virus (HIV) type 1 RNA levels and HIV disease progression was assessed in a cohort of 109

149 HIV disease progression was defined as the occurrence of

150 on of CCR5) in human immunodeficiency virus (HIV) disease progression was studied in 132 white HIV ty